ATAI Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $125 million Series C financing round, including $32 million of its 2020 convertible debt that converted in connection with the Series C.
ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
atai Life Sciences, a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a…
JOIN THE ATAI #INSIGHTNETWORK